1
|
Inhibitor of DNA binding in heart development and cardiovascular diseases. Cell Commun Signal 2019; 17:51. [PMID: 31126344 PMCID: PMC6534900 DOI: 10.1186/s12964-019-0365-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 05/14/2019] [Indexed: 02/05/2023] Open
Abstract
Id proteins, inhibitors of DNA binding, are transcription regulators containing a highly conserved helix-loop-helix domain. During multiple stages of normal cardiogenesis, Id proteins play major roles in early development and participate in the differentiation and proliferation of cardiac progenitor cells and mature cardiomyocytes. The fact that a depletion of Ids can cause a variety of defects in cardiac structure and conduction function is further evidence of their involvement in heart development. Multiple signalling pathways and growth factors are involved in the regulation of Ids in a cell- and tissue- specific manner to affect heart development. Recent studies have demonstrated that Ids are related to multiple aspects of cardiovascular diseases, including congenital structural, coronary heart disease, and arrhythmia. Although a growing body of research has elucidated the important role of Ids, no comprehensive review has previously compiled these scattered findings. Here, we introduce and summarize the roles of Id proteins in heart development, with the hope that this overview of key findings might shed light on the molecular basis of consequential cardiovascular diseases. Furthermore, we described the future prospective researches needed to enable advancement in the maintainance of the proliferative capacity of cardiomyocytes. Additionally, research focusing on increasing embryonic stem cell culture adaptability will help to improve the future therapeutic application of cardiac regeneration.
Collapse
|
2
|
Widiapradja A, Chunduri P, Levick SP. The role of neuropeptides in adverse myocardial remodeling and heart failure. Cell Mol Life Sci 2017; 74:2019-2038. [PMID: 28097372 DOI: 10.1007/s00018-017-2452-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 12/05/2016] [Accepted: 01/02/2017] [Indexed: 12/25/2022]
Abstract
In addition to traditional neurotransmitters of the sympathetic and parasympathetic nervous systems, the heart also contains numerous neuropeptides. These neuropeptides not only modulate the effects of neurotransmitters, but also have independent effects on cardiac function. While in most cases the physiological actions of these neuropeptides are well defined, their contributions to cardiac pathology are less appreciated. Some neuropeptides are cardioprotective, some promote adverse cardiac remodeling and heart failure, and in the case of others their functions are unclear. Some have both cardioprotective and adverse effects depending on the specific cardiac pathology and progression of that pathology. In this review, we briefly describe the actions of several neuropeptides on normal cardiac physiology, before describing in more detail their role in adverse cardiac remodeling and heart failure. It is our goal to bring more focus toward understanding the contribution of neuropeptides to the pathogenesis of heart failure, and to consider them as potential therapeutic targets.
Collapse
Affiliation(s)
- Alexander Widiapradja
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.,Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Prasad Chunduri
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
| | - Scott P Levick
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA. .,Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA.
| |
Collapse
|
3
|
Osadchii OE. Emerging role of neurotensin in regulation of the cardiovascular system. Eur J Pharmacol 2015; 762:184-92. [DOI: 10.1016/j.ejphar.2015.05.025] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 04/29/2015] [Accepted: 05/11/2015] [Indexed: 10/23/2022]
|
4
|
Abstract
Multiple studies have shown that the cytokine leukemia inhibitory factor (LIF) is protective of the myocardium in the acute stress of ischemia-reperfusion. All three major intracellular signaling pathways that are activated by LIF in cardiac myocytes have been linked to actions that protect against oxidative stress and cell death, either at the level of the mitochondrion or via nuclear transcription. In addition, LIF has been shown to contribute to post-myocardial infarction cardiac repair and regeneration, by stimulating the homing of bone marrow-derived cardiac progenitors to the injured myocardium, the differentiation of resident cardiac stem cells into endothelial cells, and neovascularization. Whether LIF offers protection to the heart under chronic stress such as hypertension-induced cardiac remodeling and heart failure is not known. However, mice with cardiac myocyte restricted knockout of STAT3, a principal transcription factor activated by LIF, develop heart failure with age, and cardiac STAT3 levels are reported to be decreased in heart failure patients. In addition, endogenously produced LIF has been implicated in the cholinergic transdiffrentiation that may serve to attenuate sympathetic overdrive in heart failure and in the peri-infarct region of the heart after myocardial infarction. Surprisingly, therapeutic strategies to exploit the beneficial actions of LIF on the injured myocardium have received scant attention. Nor is it established whether the purported so-called adverse effects of LIF observed in isolated cardiac myocytes have physiological relevance in vivo. Here we present an overview of the actions of LIF in the heart with the goal of stimulating further research into the translational potential of this pleiotropic cytokine.
Collapse
|
5
|
Zgheib C, Zouein FA, Kurdi M, Booz GW. Differential STAT3 signaling in the heart: Impact of concurrent signals and oxidative stress. JAKSTAT 2013; 1:101-10. [PMID: 23904970 PMCID: PMC3670289 DOI: 10.4161/jkst.19776] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Multiple lines of evidence suggest that the transcription factor STAT3 is linked to a protective and reparative response in the heart. Thus, increasing duration or intensity of STAT3 activation ought to minimize damage and improve heart function under conditions of stress. Two recent studies using genetic mouse models, however, report findings that appear to refute this proposition. Unfortunately, studies often approach the question of the role of STAT3 in the heart from the perspective that all STAT3 signaling is equivalent, particularly when it comes to signaling by IL-6 type cytokines, which share the gp130 signaling protein. Moreover, STAT3 activation is typically equated with phosphorylation of a critical tyrosine residue. Yet, STAT3 transcriptional behavior is subject to modulation by serine phosphorylation, acetylation, and redox status of the cell. Unphosphorylated STAT3 is implicated in gene induction as well. Thus, how STAT3 is activated and also what other signaling events are occurring at the same time is likely to impact on the outcome ultimately linked to STAT3. Notably STAT3 may serve as a scaffold protein allowing it to interact with other singling pathways. In this context, canonical gp130 cytokine signaling may function to integrate STAT3 signaling with a protective PI3K/AKT signaling network via mutual involvement of JAK tyrosine kinases. Differences in the extent of integration may occur between those cytokines that signal through gp130 homodimers and those through heterodimers of gp130 with a receptor α chain. Signal integration may have importance not only for deciding the particular gene profile linked to STAT3, but for the newly described mitochondrial stabilization role of STAT3 as well. In addition, disruption of integrated gp130-related STAT3 signaling may occur under conditions of oxidative stress, which negatively impacts on JAK catalytic activity. For these reasons, understanding the importance of STAT3 signaling to heart function requires a greater appreciation of the plasticity of this transcription factor in the context in which it is investigated.
Collapse
Affiliation(s)
- Carlos Zgheib
- Department of Pharmacology and Toxicology; School of Medicine; and the Center for Excellence in Cardiovascular-Renal Research; The University of Mississippi Medical Center; Jackson, MS USA
| | | | | | | |
Collapse
|
6
|
Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function. Eur Cytokine Netw 2013; 23:191-7. [PMID: 23291613 DOI: 10.1684/ecn.2012.0319] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Recent evidence suggests that the IL-6 family cytokine, leukemia inhibitory factor (LIF) is produced by cardiac cells under stress conditions including myocardial infarction and heart failure. Additionally, short-term delivery of LIF has been shown to have preconditioning effects on the heart and to limit infarct size. However, cell culture studies have suggested that LIF may exert harmful effects on cardiac myocytes, including pathological hypertrophy and contractile dysfunction. Long-term effects of LIF on the heart in vivo have not been reported and were the focus of this study. Adult male mice were injected daily with LIF (2 μg/30 g) or saline for 10 days. LIF treatment caused an approximate 11% loss in body weight. Cardiac function as assessed by echocardiography was improved in LIF-treated mice. Ejection fraction and fractional shortening were increased by 21% and 32%, respectively. No cardiac hypertrophy was seen on histology in LIF-treated mice,, there was no change in the heart-to-tibia length ratio, and no cardiac fibrosis was observed. STAT3 was markedly activated by LIF in the left ventricle. Different effects of LIF were seen in protein levels of genes associated with STAT3 in the left ventricle: levels of SOD2 and Bcl-xL were unchanged, but levels of total STAT3 and MCP-1 were increased. There was a trend towards increased expression of miR-17, miR-21, and miR-199 in the left ventricle of LIF-treated mice, but these changes were not statistically significant. In conclusion, effects of chronic LIF treatment on the heart, although modest, were positive for systolic function: adverse cardiac remodeling was not observed. Our findings thus lend further support to recent proposals that LIF may have therapeutic utility in preventing injury to or repairing the myocardium.
Collapse
|
7
|
The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure. PLoS One 2012; 7:e45489. [PMID: 23029047 PMCID: PMC3447799 DOI: 10.1371/journal.pone.0045489] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2011] [Accepted: 08/23/2012] [Indexed: 11/20/2022] Open
Abstract
A positive inotropic responsiveness to serotonin, mediated by 5-HT4 and 5-HT2A receptors, appears in the ventricle of rats with post-infarction congestive heart failure (HF) and pressure overload-induced hypertrophy. A hallmark of HF is a transition towards a foetal genotype which correlates with loss of cardiac functions. Thus, we wanted to investigate whether the foetal and neonatal cardiac ventricle displays serotonin responsiveness. Wistar rat hearts were collected day 3 and 1 before expected birth (days -3 and -1), as well as day 1, 3, 5 and 113 (age matched with Sham and HF) after birth. Hearts from post-infarction HF and sham-operated animals (Sham) were also collected. Heart tissue was examined for mRNA expression of 5-HT4, 5-HT2A and 5-HT2B serotonin receptors, 5-HT transporter, atrial natriuretic peptide (ANP) and myosin heavy chain (MHC)-α and MHC-β (real-time quantitative RT-PCR) as well as 5-HT-receptor-mediated increase in contractile function exvivo (electrical field stimulation of ventricular strips from foetal and neonatal rats and left ventricular papillary muscle from adult rats in organ bath). Both 5-HT4 mRNA expression and functional responses were highest at day -3 and decreased gradually to day 5, with a further decrease to adult levels. In HF, receptor mRNA levels and functional responses reappeared, but to lower levels than in the foetal ventricle. The 5-HT2A and 5-HT2B receptor mRNA levels increased to a maximum immediately after birth, but of these, only the 5-HT2A receptor mediated a positive inotropic response. We suggest that the 5-HT4 receptor is a representative of a foetal cardiac gene program, functional in late foetal development and reactivated in heart failure.
Collapse
|
8
|
Waehre A, Vistnes M, Sjaastad I, Nygård S, Husberg C, Lunde IG, Aukrust P, Yndestad A, Vinge LE, Behmen D, Neukamm C, Brun H, Thaulow E, Christensen G. Chemokines regulate small leucine-rich proteoglycans in the extracellular matrix of the pressure-overloaded right ventricle. J Appl Physiol (1985) 2012; 112:1372-82. [DOI: 10.1152/japplphysiol.01350.2011] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Chemokines have been suggested to play a role during development of left ventricular failure, but little is known about their role during right ventricular (RV) remodeling and dysfunction. We have previously shown that the chemokine (C-X-C motif) ligand 13 (CXCL13) regulates small leucine-rich proteoglycans (SLRPs). We hypothesized that chemokines are upregulated in the pressure-overloaded RV, and that they regulate SLRPs. Mice with RV pressure overload following pulmonary banding (PB) had a significant increase in RV weight and an increase in liver weight after 1 wk. Microarray analysis (Affymetrix) of RV tissue from mice with PB revealed that CXCL10, CXCL6, chemokine (C-X3-C motif) ligand 1 (CX3CL1), chemokine (C-C motif) ligand 5 (CCL5), CXCL16, and CCL2 were the most upregulated chemokines. Stimulation of cardiac fibroblasts with these same chemokines showed that CXCL16 increased the expression of the four SLRPs: decorin, lumican, biglycan, and fibromodulin. CCL5 increased the same SLRPs, except decorin, whereas CX3CL1 increased the expression of decorin and lumican. CXCL16, CX3CL1, and CCL5 were also shown to increase the levels of glycosylated decorin and lumican in the medium after stimulation of fibroblasts. In the pressure-overloaded RV tissue, Western blotting revealed an increase in the total protein level of lumican and a glycosylated form of decorin with a higher molecular weight compared with control mice. Both mice with PB and patients with pulmonary stenosis had significantly increased circulating levels of CXCL16 compared with healthy controls measured by enzyme immunoassay. In conclusion, we have found that chemokines are upregulated in the pressure-overloaded RV and that CXCL16, CX3CL1, and CCL5 regulate expression and posttranslational modifications of SLRPs in cardiac fibroblasts. In the pressure-overloaded RV, protein levels of lumican were increased, and a glycosylated form of decorin with a high molecular weight appeared.
Collapse
Affiliation(s)
- Anne Waehre
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| | - Maria Vistnes
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| | - Ivar Sjaastad
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
- Department of Cardiology, Oslo University Hospital Ullevål,
| | - Ståle Nygård
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
- Bioinformatics Core Facility, Institute for Medical Informatics,
| | - Cathrine Husberg
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| | - Ida Gjervold Lunde
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| | - Pål Aukrust
- Research Institute for Internal Medicine,
- Section of Clinical Immunology and Infectious Diseases, and
| | - Arne Yndestad
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
- Research Institute for Internal Medicine,
| | - Leif E. Vinge
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
- Research Institute for Internal Medicine,
- Departments of 7Cardiology and
| | - Dina Behmen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| | - Christian Neukamm
- Pediatric Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Henrik Brun
- Pediatric Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Erik Thaulow
- Pediatric Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Geir Christensen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo,
- KG Jebsen Cardiac Research Center and Center for Heart Failure Research, University of Oslo,
| |
Collapse
|
9
|
Bjørnstad JL, Skrbic B, Marstein HS, Hasic A, Sjaastad I, Louch WE, Florholmen G, Christensen G, Tønnessen T. Inhibition of SMAD2 phosphorylation preserves cardiac function during pressure overload. Cardiovasc Res 2011; 93:100-10. [DOI: 10.1093/cvr/cvr294] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Wanichawan P, Louch WE, Hortemo KH, Austbø B, Lunde PK, Scott JD, Sejersted OM, Carlson CR. Full-length cardiac Na+/Ca2+ exchanger 1 protein is not phosphorylated by protein kinase A. Am J Physiol Cell Physiol 2011; 300:C989-97. [PMID: 21289289 DOI: 10.1152/ajpcell.00196.2010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The cardiac Na(+)/Ca(2+) exchanger 1 (NCX1) is an important regulator of intracellular Ca(2+) homeostasis and cardiac function. Several studies have indicated that NCX1 is phosphorylated by the cAMP-dependent protein kinase A (PKA) in vitro, which increases its activity. However, this finding is controversial and no phosphorylation site has so far been identified. Using bioinformatic analysis and peptide arrays, we screened NCX1 for putative PKA phosphorylation sites. Although several NCX1 synthetic peptides were phosphorylated by PKA in vitro, only one PKA site (threonine 731) was identified after mutational analysis. To further examine whether NCX1 protein could be PKA phosphorylated, wild-type and alanine-substituted NCX1-green fluorescent protein (GFP)-fusion proteins expressed in human embryonic kidney (HEK)293 cells were generated. No phosphorylation of full-length or calpain- or caspase-3 digested NCX1-GFP was observed with purified PKA-C and [γ-(32)P]ATP. Immunoblotting experiments with anti-PKA substrate and phosphothreonine-specific antibodies were further performed to investigate phosphorylation of endogenous NCX1. Phospho-NCX1 levels were also not increased after forskolin or isoproterenol treatment in vivo, in isolated neonatal cardiomyocytes, or in total heart homogenate. These data indicate that the novel in vitro PKA phosphorylation site is inaccessible in full-length as well as in calpain- or caspase-3 digested NCX1 protein, suggesting that NCX1 is not a direct target for PKA phosphorylation.
Collapse
Affiliation(s)
- Pimthanya Wanichawan
- Institute for Experimental Medical Research, Oslo Univ. Hospital, Ullevaal, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Çelebi B, Elçin AE, Elçin YM. Proteome analysis of rat bone marrow mesenchymal stem cell differentiation. J Proteome Res 2010; 9:5217-27. [PMID: 20681633 DOI: 10.1021/pr100506u] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Bone marrow multipotent stromal cells (or mesenchymal stem cells; MSCs) have the capacity for renewal and the potential to differentiate in culture into several cell types including osteoblasts, chondrocytes, adipocytes, cardiomyocytes, and neurons. This study was designed to investigate the protein expression profiles of rat bone marrow MSCs during differentiation into adipogenic (by dexamethasone, isobutylmethylxanthine, insulin, and indomethacin), cardiomyogenic (by 5-azacytidine), chondrogenic (by ascorbic acid, insulin-transferrin-selenous acid, and transforming growth factor-β1), and osteogenic (by dexamethasone, β-glycerophosphate, and ascorbic acid) lineages by well-known differentiation inducers. Proteins extracted from differentiated MSCs were separated using two-dimensional gel electrophoresis (2-DE) and protein spots were detected using Sypro Ruby dye. Protein spots that were determined to be up- or down-regulated when the expression of corresponding spots (between weeks 1 and 2, 1 and 3, 1 and 4) showed an increase (≥2-fold) or decrease (≤0.5-fold) were successfully identified by MALDI-TOF-MS. In summary, 23 new proteins were identified either up- or down-regulated during differentiation experiments.
Collapse
Affiliation(s)
- Betül Çelebi
- Tissue Engineering, Biomaterials and Nanobiotechnology Laboratory, Ankara University, Faculty of Science, Biotechnology Institute, Stem Cell Institute, Ankara, Turkey
| | | | | |
Collapse
|
12
|
Røsjø H, Husberg C, Dahl MB, Stridsberg M, Sjaastad I, Finsen AV, Carlson CR, Oie E, Omland T, Christensen G. Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. Circ Heart Fail 2010; 3:503-11. [PMID: 20519641 DOI: 10.1161/circheartfailure.109.867747] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Chromogranin B (CgB) is a member of the granin protein family. Because CgB is often colocalized with chromogranin A (CgA), a recently discovered cardiac biomarker, we hypothesized that CgB is regulated during heart failure (HF) development. METHODS AND RESULTS CgB regulation was investigated in patients with chronic HF and in a post-myocardial infarction HF mouse model. Animals were phenotypically characterized by echocardiography and euthanized 1 week after myocardial infarction. CgB mRNA levels were 5.2-fold increased in the noninfarcted part of the left ventricle of HF animals compared with sham-operated animals (P<0.001). CgB mRNA level in HF animals correlated closely with animal lung weight (r=0.74, P=0.04) but not with CgA mRNA levels (r=0.20, P=0.61). CgB protein levels were markedly increased in both the noninfarcted (110%) and the infarcted part of the left ventricle (70%) but unaltered in other tissues investigated. Myocardial CgB immunoreactivity was confined to cardiomyocytes. Norepinephrine, angiotensin II, and transforming growth factor-beta increased CgB gene expression in cardiomyocytes. Circulating CgB levels were increased in HF animals (median levels in HF animals versus sham, 1.23 [interquartile range, 1.03 to 1.93] versus 0.98 [0.90 to 1.04] nmol/L; P=0.003) and in HF patients (HF patients versus control, 1.66 [1.48 to 1.85] versus 1.47 [1.39 to 1.58] nmol/L; P=0.007), with levels increasing in proportion to New York Heart Association functional class (P=0.03 for trend). Circulating CgB levels were only modestly correlated with CgA (r=0.31, P=0.009) and B-type natriuretic peptide levels (r=0.27, P=0.014). CONCLUSIONS CgB production is increased and regulated in proportion to disease severity in the left ventricle and circulation during HF development.
Collapse
Affiliation(s)
- Helge Røsjø
- Medical Division and EpiGen, Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, Lørenskog, Norway.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Dahl CP, Husberg C, Gullestad L, W�hre A, Damås JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, �ie E, Yndestad A, Christensen G. Increased Production of CXCL16 in Experimental and Clinical Heart Failure. Circ Heart Fail 2009; 2:624-32. [DOI: 10.1161/circheartfailure.108.821074] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Christen Peder Dahl
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Cathrine Husberg
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Lars Gullestad
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Anne W�hre
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Jan Kristian Damås
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Leif Erik Vinge
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Alexandra V. Finsen
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Thor Ueland
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Geir Florholmen
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Svend Aakhus
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Bente Halvorsen
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Pål Aukrust
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Erik �ie
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Arne Yndestad
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| | - Geir Christensen
- From the Research Institute for Internal Medicine (C.P.D., J.K.D., A.V.F., T.U., B.H., P.A., E.�., A.Y.), Department of Cardiology (C.P.D., L.G., A.V.F., S.A., E.�.), Section of Clinical Immunology and Infectious Diseases (J.K.D., P.A.), Section of Endocrinology (T.U.), and Institute for Surgical Research (L.E.V.), Rikshospitalet University Hospital, University of Oslo; Institute for Experimental Medical Research (C.H., A.W., A.V.F., G.F., E.�., G.C.), Ullevål University Hospital; and Center for
| |
Collapse
|
14
|
Marwood M, Visser K, Salamonsen LA, Dimitriadis E. Interleukin-11 and leukemia inhibitory factor regulate the adhesion of endometrial epithelial cells: implications in fertility regulation. Endocrinology 2009; 150:2915-23. [PMID: 19213836 DOI: 10.1210/en.2008-1538] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Embryo implantation requires the closely harmonized processes of apposition, attachment, and adhesion of the conceptus to the maternal endometrial epithelium. IL-11 and leukemia inhibitory factor (LIF), two IL-6 family cytokines, are produced by the endometrium and are absolutely required for implantation in mice. We examined the effect of IL-11 and LIF on human endometrial epithelial cell adhesion. Both cytokines increased adhesion of primary human endometrial epithelial cells to fibronectin and collagen IV. IL-11 stimulated, whereas LIF had no effect on the adhesion of trophoblast to endometrial epithelial cells. Focused oligogene arrays were used to identify extracellular matrix and adhesion molecules mRNAs regulated by endometrial epithelial cells. We demonstrated by real-time RT-PCR and antibody arrays that both cytokines increased integrin-alpha2 mRNA and protein by endometrial epithelial cells. Signal transducers and activators of transcription (STAT)-3 inhibition reduced IL-11- and LIF-mediated epithelial cell adhesion to fibronectin, suggesting both cytokines regulated adhesion via phosphorylation of STAT3. Addition of either IL-11 neutralizing antibody and IL-11 or LIF and LIF antagonist to endometrial epithelial cells abolished cytokine induced phosphorylated STAT3. LIF but not IL-11 induced adhesion to collagen IV was reduced by an integrin-alpha2beta1 neutralizing antibody. This study demonstrated that IL-11 and LIF regulated endometrial epithelial cell adhesion, suggesting that targeting IL-11 and LIF may be useful in regulating fertility by either enhancing or blocking implantation.
Collapse
Affiliation(s)
- M Marwood
- Prince Henry's Institute of Medical Research, 246 Clayton Road, Clayton, Victoria, Australia
| | | | | | | |
Collapse
|
15
|
Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30:1229-36. [DOI: 10.1093/eurheartj/ehp088] [Citation(s) in RCA: 209] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Trouillas M, Saucourt C, Guillotin B, Gauthereau X, Ding L, Buchholz F, Doss MX, Sachinidis A, Hescheler J, Hummel O, Huebner N, Kolde R, Vilo J, Schulz H, Boeuf H. Three LIF-dependent signatures and gene clusters with atypical expression profiles, identified by transcriptome studies in mouse ES cells and early derivatives. BMC Genomics 2009; 10:73. [PMID: 19203379 PMCID: PMC2674464 DOI: 10.1186/1471-2164-10-73] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2008] [Accepted: 02/09/2009] [Indexed: 12/29/2022] Open
Abstract
Background Mouse embryonic stem (ES) cells remain pluripotent in vitro when grown in the presence of the cytokine Leukaemia Inhibitory Factor (LIF). Identification of LIF targets and of genes regulating the transition between pluripotent and early differentiated cells is a critical step for understanding the control of ES cell pluripotency. Results By gene profiling studies carried out with mRNAs from ES cells and their early derivatives treated or not with LIF, we have identified i) LIF-dependent genes, highly expressed in pluripotent cells, whose expression level decreases sharply upon LIF withdrawal [Pluri genes], ii) LIF induced genes [Lifind genes] whose expression is differentially regulated depending upon cell context and iii) genes specific to the reversible or irreversible committed states. In addition, by hierarchical gene clustering, we have identified, among eight independent gene clusters, two atypical groups of genes, whose expression level was highly modulated in committed cells only. Computer based analyses led to the characterization of different sub-types of Pluri and Lifind genes, and revealed their differential modulation by Oct4 or Nanog master genes. Individual knock down of a selection of Pluri and Lifind genes leads to weak changes in the expression of early differentiation markers, in cell growth conditions in which these master genes are still expressed. Conclusion We have identified different sets of LIF-regulated genes depending upon the cell state (reversible or irreversible commitment), which allowed us to present a novel global view of LIF responses. We are also reporting on the identification of genes whose expression is strictly regulated during the commitment step. Furthermore, our studies identify sub-networks of genes with a restricted expression in pluripotent ES cells, whose down regulation occurs while the master knot (composed of OCT4, SOX2 and NANOG) is still expressed and which might be down-regulated together for driving cells towards differentiation.
Collapse
|
17
|
Larsen KO, Lygren B, Sjaastad I, Krobert KA, Arnkvaern K, Florholmen G, Larsen AKR, Levy FO, Taskén K, Skjønsberg OH, Christensen G. Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A. Cardiovasc Res 2008; 80:47-54. [PMID: 18599478 DOI: 10.1093/cvr/cvn180] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
AIMS Chronic obstructive pulmonary disease with alveolar hypoxia is associated with diastolic dysfunction in the right and left ventricle (LV). LV diastolic dysfunction is not caused by increased afterload, and we recently showed that reduced phosphorylation of phospholamban at serine (Ser) 16 may explain the reduced relaxation of the myocardium. Here, we study the mechanisms leading to the hypoxia-induced reduction in phosphorylation of phospholamban at Ser16. METHODS AND RESULTS In C57Bl/6j mice exposed to 10% oxygen, signalling molecules were measured in cardiac tissue, sarcoplasmic reticulum (SR)-enriched membrane preparations, and serum. Cardiomyocytes isolated from neonatal mice were exposed to interleukin (IL)-18 for 24 h. The beta-adrenergic pathway in the myocardium was not altered by alveolar hypoxia, as assessed by measurements of beta-adrenergic receptor levels, adenylyl cyclase activity, and subunits of cyclic AMP-dependent protein kinase. However, alveolar hypoxia led to a significantly higher amount (124%) and activity (234%) of protein phosphatase (PP) 2A in SR-enriched membrane preparations from LV compared with control. Serum levels of an array of cytokines were assayed, and a pronounced increase in IL-18 was observed. In isolated cardiomyocytes, treatment with IL-18 increased the amount and activity of PP2A, and reduced phosphorylation of phospholamban at Ser16 to 54% of control. CONCLUSION Our results indicate that the diastolic dysfunction observed in alveolar hypoxia might be caused by increased circulating IL-18, thereby inducing an increase in PP2A and a reduction in phosphorylation of phospholamban at Ser16.
Collapse
Affiliation(s)
- Karl-Otto Larsen
- Department of Pulmonary Medicine, Ullevål University Hospital, University of Oslo, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Husberg C, Nygård S, Finsen AV, Damås JK, Frigessi A, Oie E, Waehre A, Gullestad L, Aukrust P, Yndestad A, Christensen G. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45:261-9. [PMID: 18585734 DOI: 10.1016/j.yjmcc.2008.05.009] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2008] [Accepted: 05/20/2008] [Indexed: 11/19/2022]
Abstract
Several lines of evidence suggest that inflammatory processes mediated by cytokines are involved in the pathogenesis of heart failure (HF). However, the regulation of cytokine expression and the role of cytokines during HF development are not well understood. To address this issue, we have examined alterations in gene expression during HF progression by microarray technology in non-infarcted left ventricular (LV) murine tissue at various time points after myocardial infarction (MI). The highest number of regulated genes was found five days after MI. In total, we identified 14 regulated genes encoding cytokines with no previous association to HF. The strongest up-regulation was found for the chemokine fractalkine (CX3CL1). In human failing hearts we detected a 3-fold increase in CX3CL1 protein production, and both cardiomyocytes and fibrous tissue revealed immunoreactivity for CX3CL1 and its specific receptor CX3CR1. We also found that the circulating level of CX3CL1 was increased in patients with chronic HF in accordance with disease severity (1.6-fold in NYHA II, 2.2-fold in NYHA III and 2.9-fold in NYHA IV). In vitro experiments demonstrated that CX3CL1 production could be induced by inflammatory cytokines known to be highly expressed in HF. CX3CL1 itself induced the expression of markers of cardiac hypertrophy and protein phosphatases in neonatal cardiomyocytes. Given the increased CX3CL1 production in both an experimental HF model and in patients with chronic HF as well as its direct effects on cardiomyocytes, we suggest a role for CX3CL1 and its receptor CX3CR1 in the pathogenesis of HF.
Collapse
Affiliation(s)
- Cathrine Husberg
- Institute for Experimental Medical Research, Ullevaal University Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 2008; 153 Suppl 1:S414-27. [PMID: 18246092 DOI: 10.1038/bjp.2008.1] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
IL-6-type cytokines bind to plasma membrane receptor complexes containing the common signal transducing receptor chain gp130 that is ubiquitously expressed in most tissues including the heart. The two major signalling cascades activated by the gp130 receptor, SHP2/ERK and STAT pathways, have been demonstrated to play important roles in cardiac development, hypertrophy, protection and remodelling in response to physiological and pathophysiological stimuli. Experimental data, both in vivo and in vitro, imply beneficial effects of gp130 signalling on cardiomyocytes in terms of growth and survival. In contrast, it has been reported that elevated serum levels of IL-6 cytokines and gp130 proteins are strong prognostic markers for morbidity and mortality in patients with heart failure or after myocardial infarction. Moreover, it has been shown that the local gp130 receptor system is altered in failing human hearts. In the present review, we summarize the basic principles of gp130 signalling, which requires simultaneous activation of STAT and ERK pathways under the tight control of positive and negative intracellular signalling modulators to provide a balanced biological outcome. Furthermore, we highlight the key role of the gp130 receptor and its major downstream effectors in the heart in terms of development and regeneration and in response to various physiological and pathophysiological stress situations. Finally, we comment on tissue-specific diversity and challenges in targeted pharmacological interference with components of the gp130 receptor system.
Collapse
Affiliation(s)
- P Fischer
- Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
| | | |
Collapse
|
20
|
Andersson KB, Florholmen G, Winer LH, Tønnessen T, Christensen G. Regulation of neuronal type genes in congestive heart failure rats. Acta Physiol (Oxf) 2006; 186:17-27. [PMID: 16497176 DOI: 10.1111/j.1748-1716.2005.01503.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM After myocardial infarction (MI), complex changes in the heart occur during progression into congestive heart failure (CHF). This study sought to identify regulated genes that could have a functional role in some of the changes seen in CHF. METHODS Myocardial infarction was induced by ligation of the left anterior descending coronary artery (LAD) in Wistar rats. Gene expression changes in 1- and 7-day MI left ventricular myocardium was analysed using complementary DNA (cDNA) filter arrays. Regulated genes were identified by repeated measurements and a ranked ratio analysis method. RESULTS A total of 135 genes were identified as differentially expressed. A few genes were robustly regulated at 1-day MI. In 7-day CHF hearts, changes in the expression of neuronal type genes was prominent (32%, n = 28). Eleven of these genes with no described association with CHF were selected for validation. One gene failed the validation. In CHF hearts, the expression of the muscarinic m4 (Chrm4) and nicotinic alpha4 (Chrna4) acetylcholin receptors, the ATP receptor P2rx4, nerve growth factor receptor (Ngfr), discoidin domain receptor 1 (Ddr1), neuronal pentraxin receptor (Nptxr), peripheral myelin protein Pmp-22, leukocyte type 12-lipoxygenase (Alox15), cytochrome P450 4F5 (Cyp4F5) and cardiac Kcne1 were all increased (range 1.6-6.0-fold, P < 0.01 for all genes). The lack of significant regulation of these genes at 1-day post-MI, suggests that the induction of these genes at 7-day post-MI is not a short-term response induced by the infarct itself. CONCLUSION These neuronal type genes may participate in underlying processes that affect contractility, intracardiac nerve function and development of arrhythmias in CHF hearts.
Collapse
Affiliation(s)
- K B Andersson
- Institute for Experimental Medical Research, Ullevaal University Hospital, Oslo, Norway.
| | | | | | | | | |
Collapse
|
21
|
Papoian R, Scherer A, Saulnier M, Staedtler F, Cordier A, Legay F, Maurer G, Staeheli J, Vonderscher J, Chibout SD. VeloceGenomics: An Accelerated in Vivo Drug Discovery Approach to Rapidly Predict the Biologic, Drug-Like Activity of Compounds, Proteins, or Genes. Pharm Res 2005; 22:1597-613. [PMID: 16086225 DOI: 10.1007/s11095-005-6809-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2005] [Accepted: 06/22/2005] [Indexed: 12/29/2022]
Abstract
PURPOSE The aim of this study is to test the predictive power of in vivo multiorgan RNA expression profiling in identifying the biologic activity of molecules. METHODS Animals were treated with compound A or B. At the end of the treatment period, in vivo multiorgan microarray-based gene expression data were collected. Investigators masked to the identity of the compounds analyzed the transcriptome signatures to define the molecular pathways affected by treatment and to hypothesize the biologic activity and potential therapeutic indications of the blinded compounds. RESULTS For compound A, G-protein-coupled receptors and factors associated with cell growth were affected-growth hormone/insulin-like growth factor-1, glucagon/insulin axes, and general somatomedin-like activity. Deblinding showed the compound to be a somatostatin analog, SOM230, confirming the accuracy of the predicted biologic activity. For compound B, components of the inflammatory cascade potentially mediated by lipopolysaccharide, tumor necrosis factor, or proinflammatory cytokines were affected. The gene expression signatures were most consistent with an interleukin-6 family activity. Deblinding revealed that compound B was leukemia inhibitory factor. CONCLUSIONS VeloceGenomics is a strategy of coupling in vivo compound testing with genomic technologies. The process enables prediction of the mechanism of action and, coupled with other relevant data, prediction of the suitability of compounds for advancement in the drug development process.
Collapse
Affiliation(s)
- Ruben Papoian
- Department of Exploratory Development, Biomarker Development, Novartis Pharma A.G., Postfach, 4002, Basel, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111:2461-8. [PMID: 15883214 DOI: 10.1161/01.cir.0000165119.62099.14] [Citation(s) in RCA: 176] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Persistent inflammation appears to play a role in the development of heart failure (HF). Osteoprotegerin (OPG), the receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) are newly discovered members of the tumor necrosis factor superfamily that are critical regulators in bone metabolism but appear also to be involved in immune responses. We hypothesized that the OPG/RANK/RANKL axis could be involved in the pathogenesis of heart failure (HF), and this hypothesis was investigated in both experimental and clinical studies. METHODS AND RESULTS Our main and novel findings were as follows: (1) In a rat model of postinfarction HF, we found persistently increased gene expression of OPG, RANK, and RANKL in the ischemic part of the left ventricle (LV) and, for OPG, in the nonischemic part that involved both noncardiomyocyte and in particular cardiomyocyte tissue. (2) Enhanced myocardial protein levels of OPG, RANK, and RANKL, in particular, were also seen in human HF, and using immunohistochemistry, we localized these mediators to cardiomyocytes within the LV in both experimental and clinical HF. (3) In human HF, we also found increased systemic expression of RANKL (T cells and serum) and OPG (serum), with increasing levels according to functional, hemodynamic, and neurohormonal disease severity. (4) RANKL increased total matrix metalloproteinase activity in human fibroblasts, which indicates a matrix-degrading net effect and suggests a potential mechanism by which enhanced RANKL expression in HF may contribute to LV dysfunction. CONCLUSIONS These findings suggest a potential role for known mediators of bone homeostasis in the pathogenesis of HF and possibly represents new targets for therapeutic intervention in this disorder.
Collapse
Affiliation(s)
- Thor Ueland
- Research Institute for Internal Medicine, Medical Department, Rikshospitalet University Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA. Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 2005; 446:369-78. [PMID: 15806380 DOI: 10.1007/s00428-004-1177-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Accepted: 11/10/2004] [Indexed: 10/25/2022]
Abstract
This study was undertaken to investigate whether there might be differences in the distribution of extracellular matrix (ECM) proteins and matrix metalloproteinases (MMPs), depending on their specific sites within the heart. We investigated 33 explanted human hearts, 15 with dilated cardiomyopathy (DCM) and 18 with ischemic cardiomyopathy (ICM). Transmural samples from the right ventricle, the interventricular septum and the left ventricle, either from near the apex or from near the base were taken from every heart. Frozen sections were processed for connective tissue staining and immunohistochemistry for collagens type I, III, IV, laminin and fibronectin, as well as MMP-1, -2 and -9. Volume densities of laminin in ICM as well as of fibronectin and collagen types I and IV in DCM showed significant differences between right and left ventricular sites. The volume densities of matrix proteins usually did not reveal significant differences among the three left ventricular sites tested in both DCM and ICM. MMPs partly showed differences between the right and the left ventricular myocardium. These results suggest that the distributions of ECM proteins and MMPs differ between the two ventricles in both end-stage DCM and ICM. This gives rise to the hypothesis that a specific pattern of ECM degradation exists in the right and left ventricular myocardium.
Collapse
Affiliation(s)
- E Herpel
- Department of Pathology, University of Heidelberg, INF 220/1, 69120 , Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|